Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 22;26(6):1787.
doi: 10.3390/molecules26061787.

The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases

Panagiotis-Dimitrios Mingas  1 , Jurij Zdovc  1 , Iztok Grabnar  1 , Tomaž Vovk  1
Affiliations
Review

The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases

Panagiotis-Dimitrios Mingas et al. Molecules. .

Abstract

Monoclonal antibodies (mAbs) have been extensively developed over the past few years, for the treatment of various inflammatory diseases. They are large molecules characterized by complex pharmacokinetic and pharmacodynamic properties. Therapeutic drug monitoring (TDM) is routinely implemented in the therapy with mAbs, to monitor patients' treatment response and to further guide dose adjustments. Serum has been the matrix of choice in the TDM of mAbs and its sampling requires the visit of the patients to laboratories that are not always easily accessible. Therefore, dried blood spots (DBS) and various microsampling techniques have been suggested as an alternative. DBS is a sampling technique in which capillary blood is deposited on a special filter paper. It is a relatively simple procedure, and the patients can perform the home-sampling. The convenience it offers has enabled its use in the quantification of small-molecule drugs, whilst in the recent years, studies aimed to develop microsampling methods that will facilitate the TDM of mAbs. Nevertheless, hematocrit still remains an obstacle that hinders a more widespread implementation of DBS in clinical practice. The introduction of novel analytical techniques and contemporary microsampling devices can be considered the steppingstone to the attempts made addressing this issue.

Keywords: DBS; TDM; VAMS; inflammatory diseases; mAbs; microsampling.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
TDM process involving microsampling.
Figure 2
Figure 2
Current role of DBS compared to novel methods and devices.
See this image and copyright information in PMC

References

    1. Keizer R.J., Huitema A.D., Schellens J.H., Beijnen J.H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 2010;49:493–507. doi: 10.2165/11531280-000000000-00000. - DOI - PubMed
    1. Wang W., Wang E.Q., Balthasar J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 2008;84:548–558. doi: 10.1038/clpt.2008.170. - DOI - PubMed
    1. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. doi: 10.1038/256495a0. - DOI - PubMed
    1. Lu R.-M., Hwang Y.-C., Liu I.-J., Lee C.-C., Tsai H.-Z., Li H.-J., Wu H.-C. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 2020;27:1–30. doi: 10.1186/s12929-019-0592-z. - DOI - PMC - PubMed
    1. Dostalek M., Gardner I., Gurbaxani B.M., Rose R.H., Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin. Pharmacokinet. 2013;52:83–124. doi: 10.1007/s40262-012-0027-4. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources